Pneumonia Market to Grow Through 2036 Amid Emerging Therapies
The latest Pneumonia Market Insights report provides an in-depth evaluation of current treatment approaches, emerging therapeutic developments, market share distribution across available therapies, and market forecasts from 2022 to 2036. The analysis covers major healthcare markets, including the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Pneumonia Market Highlights
Pneumonia Market Highlights
- The pneumonia treatment market across major global markets is projected to experience sustained growth through 2036.
- Among all key regions, the United States represented the largest share of the pneumonia market in 2025, surpassing the combined markets of the EU4 nations, the United Kingdom, and Japan.
- In the U.S., community-acquired pneumonia (CAP) affects an estimated 24.8 adults per 10,000 individuals annually, with incidence rates rising considerably among older age groups.
- Several biotechnology and pharmaceutical companies, including Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, CanSinoBIO, Inventprise, and BioVersys, are actively advancing innovative therapies that could enter the market in the coming years.
- Key investigational treatments currently progressing through clinical development include Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, BV100, and other pipeline candidates.
Major Drivers of Pneumonia Market Expansion
Increasing Incidence of Pneumonia
Forecast analyses indicate that pneumonia cases are expected to rise between 2026 and 2036. This trend is largely attributed to demographic changes, particularly population aging. Older adults face a heightened risk of infection due to declining immune function and the increased prevalence of chronic health conditions.
Expansion of the Elderly Population
The growing global geriatric population remains a significant factor supporting market growth. Age-related immune decline and the presence of multiple comorbidities make elderly individuals more vulnerable to respiratory infections, including pneumonia.
Rising Prevalence of Chronic Disorders
Chronic diseases such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, and cardiovascular disorders increase susceptibility to pneumonia and related complications. As the burden of these conditions continues to grow worldwide, demand for effective therapies and supportive care solutions is also increasing.
Improvements in Diagnostic and Treatment Technologies
Advances in molecular testing, PCR-based diagnostics, and rapid point-of-care technologies are enabling faster and more accurate pathogen identification. Earlier diagnosis facilitates targeted treatment strategies, improving patient outcomes and supporting overall market growth.
Wider Implementation of Vaccination Programs
National healthcare initiatives and global immunization efforts promoting pneumococcal and influenza vaccines are strengthening demand for preventive measures aimed at reducing pneumonia incidence.
Introduction of Novel Therapies
The competitive landscape is expected to evolve significantly with the anticipated launch of innovative pipeline therapies, including Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, and BV100. These emerging products are expected to create new opportunities within the pneumonia treatment market.
According to Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, the pneumonia market across the seven major markets (7MM) is poised for steady expansion between 2026 and 2036. Key growth drivers include the increasing prevalence of both community-acquired and hospital-acquired pneumonia, the growing challenge of antimicrobial resistance, advancements in diagnostic technologies, and the emergence of innovative vaccines and targeted therapies.
Pneumonia Treatment Landscape
Treatment selection for pneumonia depends on factors such as the causative pathogen, disease severity, and individual patient characteristics.
Increasing Incidence of Pneumonia
Forecast analyses indicate that pneumonia cases are expected to rise between 2026 and 2036. This trend is largely attributed to demographic changes, particularly population aging. Older adults face a heightened risk of infection due to declining immune function and the increased prevalence of chronic health conditions.
Expansion of the Elderly Population
The growing global geriatric population remains a significant factor supporting market growth. Age-related immune decline and the presence of multiple comorbidities make elderly individuals more vulnerable to respiratory infections, including pneumonia.
Rising Prevalence of Chronic Disorders
Chronic diseases such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, and cardiovascular disorders increase susceptibility to pneumonia and related complications. As the burden of these conditions continues to grow worldwide, demand for effective therapies and supportive care solutions is also increasing.
Improvements in Diagnostic and Treatment Technologies
Advances in molecular testing, PCR-based diagnostics, and rapid point-of-care technologies are enabling faster and more accurate pathogen identification. Earlier diagnosis facilitates targeted treatment strategies, improving patient outcomes and supporting overall market growth.
Wider Implementation of Vaccination Programs
National healthcare initiatives and global immunization efforts promoting pneumococcal and influenza vaccines are strengthening demand for preventive measures aimed at reducing pneumonia incidence.
Introduction of Novel Therapies
The competitive landscape is expected to evolve significantly with the anticipated launch of innovative pipeline therapies, including Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, and BV100. These emerging products are expected to create new opportunities within the pneumonia treatment market.
According to Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, the pneumonia market across the seven major markets (7MM) is poised for steady expansion between 2026 and 2036. Key growth drivers include the increasing prevalence of both community-acquired and hospital-acquired pneumonia, the growing challenge of antimicrobial resistance, advancements in diagnostic technologies, and the emergence of innovative vaccines and targeted therapies.
Pneumonia Treatment Landscape
Treatment selection for pneumonia depends on factors such as the causative pathogen, disease severity, and individual patient characteristics.
- Bacterial pneumonia is commonly treated with appropriate antibiotic regimens.
- Viral pneumonia is generally managed through supportive care and, when indicated, antiviral therapies.
- Supportive interventions often include adequate hydration, rest, and hospitalization for severe infections.
- Preventive measures, particularly vaccination against pathogens such as Streptococcus pneumoniae and influenza viruses, play a critical role in reducing disease burden.
Several FDA-approved therapies are currently available for pneumonia management, including XACDURO (sulbactam/durlobactam) and ZEVTERA (ceftobiprole medocaril), among others.
At the same time, a robust pipeline featuring candidates such as Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, and BV100 is advancing through clinical development. These therapies aim to introduce novel mechanisms of action that could further improve treatment outcomes and expand therapeutic options.
Competitive Landscape and Emerging Therapies
Tosatoxumab (AR-301) – Aridis Pharmaceuticals
AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody engineered to neutralize alpha-toxin, a key virulence factor produced by Staphylococcus aureus. This toxin is present in both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains. By targeting alpha-toxin, AR-301 seeks to reduce tissue damage while preserving normal immune function. Because its activity is independent of antibiotic resistance mechanisms, the therapy may be effective against a broad range of S. aureus infections.
In July 2023, the U.S. FDA awarded AR-301 Qualified Infectious Disease Product (QIDP) designation, supporting its expedited development as an adjunctive therapy for Staphylococcus aureus pneumonia.
Results reported in September 2023 from the first of two planned global Phase III studies evaluated a single dose of AR-301 administered alongside standard antibiotic therapy in patients with ventilator-associated pneumonia caused by S. aureus. The study demonstrated a favorable safety profile. Although the microbiologically confirmed subgroup showed an 11.3% numerical improvement in clinical cure rates at Day 21, the difference did not reach statistical significance.
AON-D21 – Aptarion Biotech
AON-D21 is an investigational L-aptamer therapeutic designed to selectively inhibit complement factor C5a, a critical mediator of excessive inflammatory responses. Elevated C5a activity has been linked to severe inflammation, organ dysfunction, and increased mortality.
Preclinical studies have demonstrated promising activity in translational models of pneumonia and sepsis. Additionally, the therapy has shown potential applications in oncology, particularly in combination with immune checkpoint inhibitors for lung cancer treatment, highlighting the broader therapeutic relevance of C5a modulation.
Future Outlook
The anticipated introduction of next-generation pneumonia therapies is expected to significantly influence the future treatment landscape. As these investigational products advance through clinical development and obtain regulatory approvals, they have the potential to establish new standards of care, improve patient outcomes, stimulate innovation, and drive further growth across the global pneumonia market.
At the same time, a robust pipeline featuring candidates such as Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, and BV100 is advancing through clinical development. These therapies aim to introduce novel mechanisms of action that could further improve treatment outcomes and expand therapeutic options.
Competitive Landscape and Emerging Therapies
Tosatoxumab (AR-301) – Aridis Pharmaceuticals
AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody engineered to neutralize alpha-toxin, a key virulence factor produced by Staphylococcus aureus. This toxin is present in both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains. By targeting alpha-toxin, AR-301 seeks to reduce tissue damage while preserving normal immune function. Because its activity is independent of antibiotic resistance mechanisms, the therapy may be effective against a broad range of S. aureus infections.
In July 2023, the U.S. FDA awarded AR-301 Qualified Infectious Disease Product (QIDP) designation, supporting its expedited development as an adjunctive therapy for Staphylococcus aureus pneumonia.
Results reported in September 2023 from the first of two planned global Phase III studies evaluated a single dose of AR-301 administered alongside standard antibiotic therapy in patients with ventilator-associated pneumonia caused by S. aureus. The study demonstrated a favorable safety profile. Although the microbiologically confirmed subgroup showed an 11.3% numerical improvement in clinical cure rates at Day 21, the difference did not reach statistical significance.
AON-D21 – Aptarion Biotech
AON-D21 is an investigational L-aptamer therapeutic designed to selectively inhibit complement factor C5a, a critical mediator of excessive inflammatory responses. Elevated C5a activity has been linked to severe inflammation, organ dysfunction, and increased mortality.
Preclinical studies have demonstrated promising activity in translational models of pneumonia and sepsis. Additionally, the therapy has shown potential applications in oncology, particularly in combination with immune checkpoint inhibitors for lung cancer treatment, highlighting the broader therapeutic relevance of C5a modulation.
Future Outlook
The anticipated introduction of next-generation pneumonia therapies is expected to significantly influence the future treatment landscape. As these investigational products advance through clinical development and obtain regulatory approvals, they have the potential to establish new standards of care, improve patient outcomes, stimulate innovation, and drive further growth across the global pneumonia market.
Companies